Mankind Pharma Ltd (MANKIND)
₹2,492.80
Mkt cap
₹1.03L Cr
P/E ratio
44.30
P/B
5.85
Div yield
0.04%
ROE
13.10%
ROCE
13.50%
EPS (TTM)
₹56.27
Book value
₹426
52W range
1,910–2,642
Sector
Healthcare
Price history
Previous close
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. [1]
NSE MANKINDBSE 543904
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−5.65% from high₹2,493
₹1,910+30.53% from low₹2,642
Current
₹2,492.80
Prev close
₹2,469.30
Day
+0.95%
Price performance
1D
+0.95%
1W
+12.66%
1M
−2.05%
3M
−3.23%
6M
+10.46%
1Y
+1.71%
YTD
+13.17%
Financials
Revenue, profit & margin
P/E ratio
44.3×
MANKIND is 29% above the sector median of 34.4×
MANKIND44.3×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,708 | 2,607 | 2,422 | 2,868 | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 | 4,338 | |
| Expenses | 2,025 | 2,000 | 1,836 | 2,196 | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 | 2,974 | 3,167 | |
| Operating Profit | 683 | 606 | 586 | 672 | 847 | 816 | 683 | 847 | 921 | 919 | 930 | 1,056 | 1,171 | |
| OPM % | 25% | 23% | 24% | 23% | 28% | 26% | 22% | 24% | 25% | 26% | 27% | 26% | 27% | |
| Other Income | 63 | 75 | 94 | 108 | 109 | 87 | 249 | 83 | 94 | -31 | 94 | 49 | 99 | |
| Interest | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 | 105 | |
| Depreciation | 96 | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 | 236 | |
| Profit before tax | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 540 | 624 | 509 | 659 | 769 | 929 | |
| Tax % | 20% | 18% | 17% | 18% | 22% | 22% | 17% | 18% | 17% | 19% | 15% | 25% | 23% | |
| Net Profit | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 | 716 | |
| EPS in Rs | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.22 | 10.20 | 10.62 | 12.39 | 9.90 | 13.43 | 13.75 | 17.23 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.22% · closed higher next day 8 of last 15
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 31 Jan '24◦ | 15 May '24◦ | 31 Jul '24◦ | 5 Nov '24◦ | 24 Jan '25 | 21 May '25◦ | 31 Jul '25◦ | 6 Nov '25◦ | 3 Feb '26◦ | 19 May '26◦ | 30 Jul '26 | 26 Oct '26 |
| Earnings day | +2.32% | −4.48% | −1.15% | +1.27% | −4.86% | −3.64% | −0.04% | −2.05% | −3.39% | +3.66% | −0.65% | +4.49% |
| +1 day | +1.77% | −4.57% | −1.38% | +0.47% | −6.87% | −3.91% | +2.40% | −3.14% | −3.80% | +0.86% | −4.75% | +13.10% |
| +5 days | +12.49% | −4.14% | +2.18% | −6.71% | −7.58% | −2.75% | −3.90% | −1.82% | −3.50% | −2.90% | −6.65% | — |
| +15 days | +9.46% | −1.57% | +16.49% | −5.64% | −5.08% | −5.59% | −0.39% | −2.52% | −0.32% | −4.81% | −8.01% | — |
| +30 days | +9.19% | −2.81% | +23.21% | +3.35% | −12.11% | −6.70% | +0.10% | −5.93% | −7.48% | +1.44% | −13.67% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202672.62%Promoter
Promoters72.62%
FIIs9.37%0.08
DIIs15.54%0.15
Public2.46%0.07
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 96.96 | 1,29,914 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Mankind Pharma | ₹2,492.80 | 44.29 | 1,03,303 | 0.04% | 716 | +39.09% | 4,338 | +17.33% | 13.53% |
| Median: 158 Co. | ₹426.38 | 34.42 | 1,920 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Concall transcripts43
TranscriptOct 2026PPTOct 2026RECOct 2026PPTOct 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025TranscriptNov 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Earnings Call Transcript 30 Oct - Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27Announcement under Regulation 30 (LODR)-Credit Rating 29 Oct - CRISIL reaffirmed ratings on ₹2,500 crore NCDs and withdrew ratings on ₹1,500 crore commercial paper.Announcement under Regulation 30 (LODR)-Investor Presentation 27 Oct - In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional …Announcement under Regulation 30 (LODR)-Newspaper Publication 27 Oct - Newspaper Advertisment - Unaudited Fianncial Results of the Company for Q2 & H1 FY27Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 26 Oct - Audio recording of Q2 and H1 FY27 earnings conference call is available.